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Introduction
Alcoholic (ASH) and nonalcoholic (NASH) steatohep-
atitis are chronic liver diseases that are increasingly sig-
nificant (1). ASH affects millions of patients worldwide
and is one of the major causes of death in developed
countries (2). The progression of ASH is characterized
by steatosis (fatty infiltration), inflammation, necrosis,
and finally fibrosis and cirrhosis; when severe hepatitis
occurs, death is a common outcome (3). There are cur-
rently no effective pharmacological reagents that can
prevent or reverse this disease.
The mechanisms underlying alcohol-induced hepa-
totoxicity are complex and multifactorial. Many
recent studies suggest that several proinflammatory
cytokines produced by activated Kupffer cells might
be involved in the onset of alcoholic liver disease (4,
5). For instance, elevated circulating levels of TNF-α,
IL-1β, and IL-6 have been observed in human patients
and animal models of alcohol-induced liver injury (6,
7). The expression levels of these cytokines correlate
well with the course of the disease. The pivotal role of
these cytokines in the pathogenesis of alcoholic
steatohepatitis are further supported by the finding
that depletion of Kupffer cells prevents alcohol-
induced early liver injury in an intragastric alcohol-
fed model (8) and also suppresses alcohol-induced
microvesicular and macrovesicular steatosis in an
oral, alcohol-fed model (9). Alcoholic liver injury is
significantly attenuated by administration of Ab’s
against TNF-α (10) and is diminished in TNF-α
receptor 1 knockout mice (11). Furthermore, treat-
ment with thalidomide, a compound that inhibits
TNF-α production in Kuppfer cells, completely pre-
vents alcoholic liver injury in rats (12).
In contrast to proinflammatory cytokines, anti-inflam-
matory cytokines have been shown to have hepato-
protective effects (7). Thus, plasma levels of IL-10 in
mice are decreased by alcohol, and IL-10 knockout
mice are more susceptible to alcoholic liver injury (13).
It has been postulated that an imbalance exists between
pro- and anti-inflammatory cytokines in the liver dur-
ing chronic exposure to alcohol.
NASH is a clinicopathological syndrome that is
closely associated with obesity, insulin resistance,
and type 2 diabetes (14). It is now recognized that
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NASH is a major contributor to overall obesity-relat-
ed morbidity and mortality (15). At least 20% of
patients with this condition develop cirrhosis, a lead-
ing cause of death in this population. Although the
primary etiology of NASH is different from that of
ASH, these two diseases show almost identical his-
tology, including hepatic steatosis and lobular
inflammation. There is also evidence suggesting that
both diseases share similar pathogenesis and benefit
from similar therapies (5, 16).
Adiponectin (also called ACRP30 and GBP28) is a
protein exclusively secreted from adipose tissue (17).
This protein shares sequence homology with a family
of proteins that show modular design, a characteristic
NH2-terminal collagen-like region and a COOH-ter-
minal, complement factor C1q-like globular domain.
Interestingly, although the three-dimensional structure
of adiponectin closely resembles that of TNF-α (18),
these two proteins have completely opposite effects.
Both in vivo and in vitro experiments demonstrated
that adiponectin and TNF-α suppress each other’s pro-
duction and also antagonize each other’s action in their
target tissues (19). Administration of adiponectin into
mice has been shown to produce beneficial effects on
lipid metabolism, such as enhancing lipid clearance
from plasma and increasing fatty acid β oxidation in
muscle (20, 21). Recent studies from Scherer’s group
and our laboratory suggest that adiponectin can act
directly on hepatic tissue and inhibit glucose produc-
tion (22, 23). Adiponectin also has direct anti-inflam-
matory effects (24). These results collectively indicate
that adiponectin might have hepatoprotective effects.
Accordingly, we tested this hypothesis in mouse mod-
els with alcoholic and nonalcoholic liver diseases. Our
results show that adiponectin is effective in alleviating
both alcohol- and obesity-associated liver abnormality,
including hepatomegaly, steatosis, and the elevated lev-
els of serum alanine aminotransferase (ALT). The
potential mechanisms include induction of hepatic
fatty acid oxidation, inhibition of fatty acid synthesis,
and suppression of TNF-α production in the liver.
Methods
Animals and diets. Male FVB/n mice weighing 25–30 g
were housed in stainless steel wire-bottom cages on a
12-hour light/12-hour dark cycle under the institu-
tional guidelines for the humane treatment of labora-
tory animals. All the experimental protocols were
approved by the Institutional Animal Ethics Commit-
tee. Mice were fed with a modified high-fat/low-carbo-
hydrate liquid diet (25) containing 44% fat, 16% pro-
tein, 5.5% carbohydrate plus 34.5% ethanol or isocaloric
maltose dextrin as the control. Ethanol concentration
was gradually increased from 17% to 34% during the
first week of feeding and then maintained at the same
concentration for another 5 weeks. Mice that were
offered ethanol-containing liquid diets as their sole
food source consumed 15.0 ± 1.3 ml/d/mouse. The
dietary intake of control groups was matched to that
of the ethanol-fed group by pair-feeding the same vol-
ume of isocaloric liquid diet.
Adult (aged 8–10 weeks) ob/ob C-57BL-6 mice and
their age-matched lean littermates were obtained from
The Jackson Laboratory (Bar Harbor, Maine, USA). The
mice were fed with standard rodent pellet food. All
mice used in this study are male, and the body weight
of each mouse was measured every 2 days for the dura-
tion of this study.
Measurement of circulating adiponectin, TNF-α, insulin,
and ALT levels. The protocol for collecting human
blood samples from obese individuals was approved by
the Ethics Committee of the Medical Faculty, Univer-
sity of Hong Kong. Blood was obtained after 12-hour
overnight fasting. All subjects provided written
informed consent before participation.
Serum levels of mouse and human adiponectin were
determined using an in-house RIA assay, using a rab-
bit polyclonal Ab against mouse adiponectin and
human adiponectin, respectively (23). Serum was
diluted 1,000-fold before assay. One hundred micro-
liters of diluted serum or standard samples of recom-
binant mouse or human adiponectin were then incu-
bated with adiponectin tracer labeled with125I and
rabbit antiadiponectin polyclonal Ab’s at room tem-
perature overnight. The immunocomplexes were
recovered by polyethylene glycerol (PEG) precipitation.
Intra- and interassay coefficients of variance were 5.2%
and 5.7%, respectively.
Circulating levels of mouse TNF-α and insulin were
quantified using commercial ELISA kits from Chemi-
con International (Temecula, California, USA) and Mer-
codia AB (Uppsala, Sweden), respectively. Serum levels
of ALT were determined using commercial reagents
from Sigma-Aldrich (St. Louis, Missouri, USA).
Measurement of hepatic fatty acid oxidation. Liver slices
were taken at the time of slaughter and rapidly excised
and cooled in ice-cold buffer consisting of 0.25 M
sucrose, 2 mM Na2-EDTA, and 10 mM Tris-HCl (pH
7.4). Whole-tissue homogenate (5% wt/vol) was pre-
pared in the same buffer using a glass homogenizer
with an intervening space of 0.050 mm. The rates of
palmitate oxidation were analyzed in tissue homo-
genate as described previously (26). Briefly, palmitate
oxidation was performed in a total volume of 0.5 ml
containing 25 µl of liver homogenates in an assay buffer
with 25 mM sucrose, 75 mM Tris-HCl (pH 7.4), 10 mM
K2HPO4, 5 mM MgCl2, 1 mM NAD+, 1 mM Na2-EDTA,
5 mM ATP, 25 µM cytochrome c, 0.1 mM coenzyme A,
0.5 mM L-malate, and 0.5 mM L-carnitine. Flasks were
preincubated for 30 minutes at 37°C before adding 100
µl of 600 µM [1-14C]palmitate (Amersham Biosciences,
Uppsala, Sweden) bound to albumin in a 5:1 ratio. Incu-
bation was carried out for 30 minutes at 37°C with agi-
tation and stopped by adding 0.2 ml of 3 M perchloric
acid. The released 14CO2 was trapped by 0.3 ml
ethanolamine/ethylene glycerol (1:2 vol/vol). After incu-
bating for 90 minutes at 4°C, the acid incubation mix-
ture was centrifuged for 5 minutes at 10,000 g, and the
supernatant containing 14C-labeled perchloric acid–sol-
uble products was subjected to liquid scintillation
counting. The rates of palmitate oxidation were calcu-
lated from the sum of 14CO2 and 14C-labeled perchloric
acid–soluble products. Blanks were prepared by adding
0.2 ml of 3 M perchloric acid to the liver homogenates
before incubating with the assay buffer for 30 minutes.
Measurement of carnitine palmitoyltransferase I activity.
Primary hepatocytes from mice fed with liquid con-
trol diet, liquid ethanol diet, or liquid ethanol diet
plus adiponectin treatment were isolated as we
described previously (23). The enzyme activity was
assessed in digitonin-permeablized cells by monitor-
ing the incorporation of L-[1-3H] carnitine and palmi-
toyl-CoA into palmitoylcarnitine. Reactions were per-
formed in 700 µl of assay buffer containing 50 mM
imidazole, 70 mM KCl, 80 mM KCN, 1 mM ATP, 0.1%
fatty acid–free BSA, 70 µM palmitoyl-CoA, 50 µg/ml
digitonin, 0.5 mM 3H L-carnitine, with or without 50
µM malonyl-CoA. Further details of this assay were
described elsewhere (27, 28).
Determination of the activities for hepatic acetyl-CoA car-
boxylase and fatty acid synthase. The activity of hepatic
fatty acid synthase (FAS) was analyzed by measuring
the incorporation of [1-14C]-acetyl-CoA into fatty acids
in the presence of malonyl-CoA (29). Liver slices were
homogenized (25% homogenate wt/vol) in a buffer
containing 10 mM HEPES (pH 7.5) and 0.25 mM
sucrose and then centrifuged for 5 minutes at 12,000 g.
The reactions were initiated by adding 0.5 mg proteins
from the centrifuged (12,000 g) supernatant into a pre-
warmed buffer consisting of 200 mM HEPES, pH 6.8,
250 mM sucrose, 1 mM NADPH, 0.88 mM DTT, 2 mM
EDTA, 2% BSA, 0.39 mM malonyl-CoA, and 0.124 mM
[1-14C]-acetyl-CoA (Amersham Biosciences). Newly syn-
thesized 14C-labeled fatty acids were extracted and
quantified as described (30).
A cytosolic fraction containing acetyl-CoA carboxylase
(ACC) was isolated from liver tissue according to the
PEG precipitation method (31). The ACC activity in the
PEG fraction was assessed using CO2 fixation technique
(31). Briefly, 12.5 µg protein was added into a reaction
buffer containing 60.6 mM Tris acetate (pH 7.5), 1
mg/ml BSA, 1.32 µM ATP, 2.12 nM β-mercaptoethanol,
5 mM magnesium acetate, 1.06 mM acetyl-CoA, 18.08
mM NaH14CO3 (Amersham Biosciences), and 2 mM
magnesium citrate. Samples were incubated at 37°C for
4 minutes and stopped by adding 25 µl of 10% perchlo-
ric acid. Newly synthesized 14C-labeled malonyl-CoA
was extracted and quantified as described (31).
Measurement of glucose, triglyceride, and FFA concentra-
tions. Blood glucose from the tail vein was measured
using Accu-Chek Comfort Glucometer (Roche Diag-
nostics, Basel, Switzerland). The levels of plasma FFA
and triglycerides (TGs) were determined using a Roche
FFA kit and Triglyceride GPO reagent (Pointe Scientif-
ic Inc., Lincoln Park, Michigan, USA), respectively.
Hepatic TG was extracted from frozen liver tissue using
chloroform/methanol (2:1), separated, and then quan-
tified colorimetrically as described (32).
Production of recombinant adiponectin from HEK293 cells.
Full-length adiponectin was expressed in HEK293 cells
transiently transfected with a vector that encodes FLAG
epitope-tagged mouse adiponectin, as described previ-
ously (23). Recombinant adiponectin was purified
using anti-FLAG M2 affinity gel (Sigma-Aldrich) and
was eluted with 150 µg/ml FLAG peptide. The eluted
protein was concentrated using a concentrator with
molecular-weight cut-off of 10,000 Da (Vivascience AG,
Hannover, Germany). FLAG peptides were removed by
an extensive wash with an excessive volume of saline.
Highly sensitive matrix-assisted laser desorption/ion-
ization time of flight (MALDI-TOF) mass-spectromet-
ric analysis confirmed that FLAG peptide was not
detectable in the protein solution.
RNA extraction and Northern blot analysis. Total RNA was
extracted from liver tissue using Trizol reagent (Invit-
rogen Corp., San Diego, California, USA). Twenty
micrograms of total RNA from each sample was sepa-
rated by denaturing agarose gels, transferred onto nylon
membrane, and probed with 32P-labeled cDNA frag-
ments encoding mouse TNF-α, FAS, ACC, or CD36.
The relative mRNA abundance of each gene was quan-
tified using PhosphorImaging.
Histological analysis. Liver specimens were fixed
overnight in buffered formaldehyde (10%) and embed-
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Figure 1
Chronic alcohol consumption decreases plasma adiponectin, increases TNF-α, and induces liver injury. Plasma samples were collected at
different stages after mice had been fed with either high-fat LC diet (dashed line) or high-fat LE diet (solid line) and then were quantified for
the levels of plasma adiponectin (a), ALT (b), and TNF-α (c), as described in the text. *P < 0.05 for ethanol diet versus control diet (n = 6).
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Plasma adiponectin decreased 32.1% ± 2.9% after 3
weeks and 40.3% ± 4.6% after 4 weeks of feeding with the
LE diet (Figure 1a). Decreased adiponectin correlated
closely with the development of liver injury, as judged
by the plasma levels of ALT activity (Figure 1b). More-
over, there was an inverse relationship between circulat-
ing concentrations of adiponectin and TNF-α level fol-
lowing chronic consumption of the LE diet (Figure 1c).
Recombinant adiponectin markedly attenuated ethanol-
induced liver injury. We next investigated the effect of
adiponectin on alcohol-induced liver injury by infusion
of full-length recombinant protein produced from
HEK293 cells. Three weeks after being fed with the LE
diet, the mice were surgically implanted with an ALZET
osmotic pump (DURECT Corp., Cupertino, California,
ded in paraffin. H&E-stained sections were graded
blindly for the degree of fatty change, inflammation,
and necrosis. Ten low-power fields were examined per
liver. The degree of lipid infiltration was graded from 0
to 4, with 0 indicating no fat present and 4 indicating
that 75% or more of the cells contain fat.
Statistical analysis. Experiments were performed rou-
tinely with five to six mice per group with values pre-
sented as mean plus or minus SD. All the studies were
replicated with representative data shown. Statistical
significance was determined by one-way ANOVA. In all
statistical comparisons, a P value of less than 0.05 was
used to indicate a significant difference.
Results
Chronic ethanol consumption causes significant decrease of cir-
culating adiponectin in mice. Mice fed with a modified high-
fat liquid ethanol (LE) diet and pair-fed with high-fat liq-
uid control (LC) diet (25) gained weight throughout the
6-week treatment period. Although the weight gain of
LC mice (7.2 ± 0.6 g) was slightly higher, it was not sig-
nificantly different from that of mice on the LE diet 
(6.8 ± 0.5 g). Mice fed with the LE diet consumed ethanol
at approximately 17–19 g/kg body weight per day. At
necropsy, liver-to-body weight ratios in mice receiving
ethanol (8.3% ± 0.6%) were significantly higher than
those in mice fed with the control diet (6.2% ± 0.4%).
Chronic ethanol consumption caused a significant
decrease in circulating concentrations of adiponectin.
Figure 2
Effects of adiponectin treatment on food intake,
body weight gains, and circulating levels of glucose
and insulin. (a) Serum adiponectin levels in mice fed
with LC diet, LE diet, or LE diet plus adiponectin infu-
sion (LE + Ad), as described in the text (n = 5). Serum
samples were collected at different times following
adiponectin treatment. (b) Food intake in LE diet
mice treated with or without adiponectin (n = 6). (c)
Average daily body weight gains over 2 weeks of
adiponectin treatment (n = 6). (d) Fasting glucose
levels over adiponectin treatment period (n = 6). (e)
Fasting plasma insulin levels over adiponectin treat-
ment period (n = 6). Note that adiponectin and alco-
hol treatment also have no obvious effects on plas-
ma levels of insulin and glucose in the fed state (data
not shown). *P < 0.001 for adiponectin-treated
group versus other two groups.
Figure 3
Adiponectin treatment ameliorates alcohol-induced dyslipidemia
and hepatic abnormality in mice. Serum samples were collected
after 5 weeks of LC diet, LE diet, or LE + Ad diet in the last 2 weeks.
Serum levels of TG (a) and FFA (b), liver-to-body weight ratio (c),
hepatic TG contents (d), and plasma ALT levels (e) were deter-
mined at necropsy (n = 5). #P < 0.05, ##P < 0.01 for LC-treated mice
versus LE-treated mice; *P < 0.05, **P < 0.01 for LE + Ad–treated
mice versus LE-treated mice.
USA), which delivered 30 µg/d adiponectin or physio-
logical saline as control. Delivery of adiponectin at this
dosage caused approximately 2.7-fold elevation in the
circulating concentration of adiponectin over that of
untreated LE mice. The elevated concentration of plas-
ma adiponectin remained constant throughout the
course of treatment (Figure 2a). Adiponectin treatment
had no obvious effects on food intake, body weight
gains, and the levels of blood glucose and insulin (Fig-
ure 2, b–e), whereas it could decrease the elevated plas-
ma concentrations of TG and FFA (Figure 3, a and b).
Notably, continuous administration of adiponectin for
2 weeks significantly decreased the ratio of liver-to-body
weight (Figure 3c), dramatically reduced hepatic lipid
content (Figure 3d), and also markedly alleviated alco-
hol-induced elevation of serum ALT levels (Figure 3e).
Histological evaluation of liver specimens demon-
strated massive panlobular microvesicular and
macrovesicular steatosis and occasional foci of inflam-
mation in mice fed with LE diet alone (Figure 4).
Administration of adiponectin dramatically decreased
lipid accumulation to a background level and largely
diminished inflammation (as judged by the absence of
inflammatory foci under microscopy). Thus, our
results demonstrated a protective role of adiponectin
in alcohol-induced liver injury in mice.
Administration of adiponectin decreased hepatic expression
of TNF-α and its plasma concentrations. Elevated produc-
tion of TNF-α from Kuppfer cells within the liver tissue
is thought to be a key mediator of early alcohol-induced
liver injury (5). A recent knockout study suggests that
TNF-α and adiponectin may antagonize each other’s
actions by each suppressing the other’s expression (19).
We thus tested the hypothesis that adiponectin might
alleviate alcohol-induced liver injury partly by sup-
pressing alcohol-induced elevation of TNF-α produc-
tion. Indeed, treatment of LE diet mice with recombi-
nant adiponectin blunted the alcohol-induced increase
of circulating TNF-α as well as mRNA production of
this cytokine in the liver (Figure 5).
Adiponectin treatment restored alcohol-induced suppression
of CPT I activity and enhanced hepatic fatty acid oxidation.
Impaired fatty acid oxidation plays a key role in alco-
holic steatosis (33). Alcohol has been shown to decrease
hepatic fatty acid oxidation in vivo and in vitro. Alco-
hol metabolism alters the intramitochondrial redox
potential, which in turn impairs β oxidation and tri-
carboxylic acid cycle activity (34). In addition, both
long-term and short-term alcohol consumption has
been shown to suppress the activity of CPT I, a rate-lim-
iting enzyme involved in the transport of long-chain
fatty acids into mitochondrial matrix (35, 36). A trun-
cated globular adiponectin can enhance fatty acid oxi-
dation in muscle (21). We next investigated whether
adiponectin-induced depletion of hepatic lipid accu-
mulation was caused partly by enhancing fatty acid oxi-
dation in this tissue. Indeed, consumption of LE diet
significantly decreased the rate of hepatic fatty acid oxi-
dation and also reduced CPT I activity (Figure 6). These
ethanol-induced alterations were restored following
adiponectin treatment.
Adiponectin treatment decreased the enzyme activities
involved in fatty acid synthesis. In addition to the suppres-
sion of fatty acid oxidation, enhanced fatty acid syn-
thesis also contributes to alcohol-induced fatty liver,
especially at the later stage of alcoholism. Chronic
ethanol consumption can increase fatty acid synthesis
in humans and rodents by inducing the expression of
key enzymes in the lipogenic pathway (37, 38). We next
investigated the effects of adiponectin on two key
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Figure 4 
Effects of adiponectin on alcohol-induced steatosis and inflam-
mation. Liver specimens were taken from mouse livers after 5 weeks
of LC diet (a and d), LE diet (b and e), or LE + Ad diet (c and f) for
the last 2 weeks and were stained with either red oil O (a–c) or H&E
(d–f). The results are representative photomicrographs from six
independent experiments.
Figure 5
Adiponectin treatment decreases alcohol-induced elevation of hepat-
ic TNF-α expression and its plasma concentrations. (a) Total RNA
from livers of mice treated with LC diet, LE diet, or LE + Ad diet was
extracted and subjected to Northern blot analysis. (b) The results
from a were quantified by PhosphorImaging (n = 5). All RNA levels
are expressed relative to untreated LC pair-fed controls, after being
normalized against the abundance of 18S RNA. (c) Plasma concen-
trations of TNF-α as measured at necropsy (n = 5). **P < 0.01 for 
LE + Ad–treated mice versus mice receiving LE diet alone.
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enzymes involved in hepatic lipogenesis, including
ACC and FAS. Consumption of the LE diet caused a
slight, but not significant increase of hepatic ACC
activity (Figure 7a). Compared with the untreated LE
diet mice, however, adiponectin caused a marked
reduction of this enzyme activity. The activity of hepat-
ic FAS was significantly increased following 5 weeks of
LE diet, and the elevated enzyme activity was markedly
decreased following adiponectin treatment (Figure 7b).
Northern blot analysis revealed that the steady-state
mRNA abundance of hepatic ACC was not altered fol-
lowing adiponectin treatment (Figure 7, c and d).
Expression of hepatic FAS was significantly elevated
following consumption of the LE diet, and adiponectin
could suppress the hepatic mRNA expression of this
enzyme. In addition, the hepatic expression of CD36, a
fatty acid transport protein, was markedly inhibited
following adiponectin treatment.
Adiponectin treatment ameliorates nonalcoholic fatty liver
disease in ob/ob mice. NASH, which is often associated
with obese individuals and patients with insulin resist-
ance and type 2 diabetes, is an important feature of
metabolic syndromes (1, 39). Anti-diabetes drugs
might also improve fatty liver disease (40). Recombi-
nant adiponectin has been shown to be effective in
increasing insulin sensitivity and in decreasing hyper-
lipidemia in several animal models (20, 41). Therefore,
we investigated the potential effects of adiponectin
treatment on fatty liver disease in obese, ob/ob mice,
which spontaneously develop hyperinsulinemia,
insulin resistance, and steatosis owing to an inherited
leptin deficiency (42). Adiponectin expression from adi-
pose tissue is markedly reduced in ob/ob mice (43).
Notably, overproduction of TNF-α in the liver tissue
has been proposed to play a key role in the pathogene-
sis of fatty liver disease in this model (5). Fatty liver dis-
ease in ob/ob mice was significantly improved by inhi-
bition of hepatic TNF-α overproduction or infusion of
anti–TNF-α neutralizing Ab (16, 40).
Consistent with those of LE diet–treated mice (Figure
2a), infusion of adiponectin using osmotic pumps (1.5
mg/kg body weight per day for 2 weeks) elevated plas-
ma adiponectin levels approximately 2.7-fold through-
out the course of the treatment. Adiponectin treat-
ments had no obvious effects on body weight gains,
food intake, and plasma levels of glucose and insulin,
whereas circulating concentration of both TG and FFA
were significantly decreased compared with untreated
ob/ob mice (Table 1). In line with a recent study (44),
infusion of adiponectin into obese ob/ob mice increased
glucose tolerance as well as insulin sensitivity (Figure
8, a and b). Notably, adiponectin improved fatty liver
disease in this animal model. Following 2 weeks of
adiponectin treatment, the liver-to-body weight ratios
were significantly reduced (Figure 8c), and this change
was associated with the decreases in hepatic lipid con-
tents (Figure 8d) and serum ALT levels (Figure 8e). The
increased hepatic production of TNF-α in the obese
mice was also significantly suppressed following
adiponectin treatment (Figure 8f). Thus, adiponectin
is an effective polypeptide for the treatment of obesity-
associated nonalcoholic fatty liver disease.
Adiponectin levels negatively correlate with serum ALT con-
centrations in morbidly obese Chinese individuals. The
results above suggest that adiponectin is associated
with alcohol- and obesity-induced fatty liver diseases.
To explore the clinical relevance of these findings, we
Figure 6
Effects of adiponectin on alcohol-induced suppression of hepatic
CPT I activity (a) and fatty acid oxidation (b). Three groups of ani-
mals were treated with LC diet, LE diet, or LE + Ad diet as described
in Figure 4. The activity of CPT I was determined by measuring 
3H palmitoylcarnitine formed in digitonin-permeabilized hepato-
cytes. The rates of fatty acid oxidation were analyzed by monitoring
nanomoles of [1-14C]palmitate oxidized per gram of liver tissue per
minute. #P < 0.05 for LC-treated mice versus LE-treated mice; 
*P < 0.05 for LE + Ad–treated mice versus LE-treated mice.
Figure 7
Effects of adiponectin on proteins involved in fatty acid synthesis and
uptake. Three groups of animals were treated with LC diet, LE diet,
or LE + Ad diet as described in Figure 4. (a) Activity of hepatic ACC
expressed as nanomoles of 14C malonyl-CoA produced per milligram
of protein per minute. (b) Hepatic FAS activity expressed as
nanomoles of 14C-labeled fatty acids produced per milligram of pro-
tein per minute. (c) Northern blot analysis of steady-state mRNA lev-
els for ACC, FAS, and CD36. (d) The results from c were quantified
by PhosphorImaging (n = 5). All mRNA levels are expressed relative
to untreated LC pair-fed controls, after being normalized against the
abundance of 18S RNA. #P < 0.05, ##P < 0.01 for LC-treated mice
versus LE-treated mice; *P < 0.05, **P < 0.01 for LE + Ad–treated
mice versus LE-treated mice.
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next investigated the relationship between plasma lev-
els of adiponectin and of ALT (a marker of liver
injury) in 90 morbidly obese Chinese individuals (age
42 ± 9; BMI 40.1 ± 5.2). The rationale for this analysis
is that there is a strong association between obesity
and NASH. The prevalence of NASH among obese
subjects is sixfold higher compared with lean individ-
uals (45). Indeed, after adjustment for age, sex, and
BMI, plasma levels of adiponectin inversely correlat-
ed with that of ALT (Figure 9), suggesting that
hypoadiponectinemia may partly account for high
incidence of NASH in obese individuals. Further
prospective and cross-sectional studies are needed to
ascertain the role of adiponectin in the cause of ASH
and NASH in humans.
Discussion
Recent studies from several independent laboratories
have demonstrated that adiponectin and its agonists
could be promising candidates for the treatment of
obesity-associated metabolic syndromes (17). Adipose
mRNA expression and plasma concentration of
adiponectin are decreased dramatically in a variety of
animal models as well as clinical patients with obesity,
type 2 diabetes, and coronary heart disease (20, 46, 47).
Replenishment of adiponectin can decrease hyper-
glycemia by inhibiting hepatic glucose pro-
duction in mice (22). It can also improve dys-
lipidemia and decrease lipid accumulation in
muscle, thus enhancing insulin sensitivity in
this tissue (20). Chronic administration of a
truncated COOH-terminal domain of
recombinant adiponectin into mice con-
suming a high-fat diet has been shown to
cause sustained and profound weight loss
without affecting food intake (21). In addi-
tion to its antidiabetic and antiobesity
effects, adiponectin has antiatherogenic
potential. This protein accumulates in
injured vessel walls and dose dependently
inhibits TNF-α–induced cell adhesion in human aortic
endothelial cells (24). These direct antidiabetic and
antiatherogenic actions have been further confirmed
by two recent independent knockout studies that
demonstrated that depletion of adiponectin induced
insulin resistance as well as neointimal formation after
vessel injury (19, 41).
In this study, we showed that decreased expression
of adiponectin might be partially responsible for alco-
hol-induced liver injury in mice (Figure 1). The mech-
anisms that underlie alcohol-induced reduction of
adiponectin expression could be due to the elevated
levels of TNF-α, which suppress adiponectin expres-
sion in adipose tissue through a paracrine or endo-
crine mechanism. Both circulating concentrations of
TNF-α and local production of TNF-α in adipose tis-
sue are increased at the early stage of alcoholic liver
injury (48). Incubation of adipocytes with TNF-α
markedly decreased expression of adiponectin (49). In
addition, it is possible that alcohol may act directly on
adipocytes and suppress adiponectin expression.
Indeed, chronic consumption of alcohol in rats has
been shown to increase relative expression of het-
erotrimeric guanosine triphosphate binding protein
stimulatory α subunit (Gsα) to the inhibitory α sub-
unit (Giα) in adipocyte membranes and to induce acti-
Figure 8
Adiponectin increases insulin sensitiv-
ity and ameliorates fatty liver diseases
in obese ob/ob mice. Age- and sex-
matched lean control mice (lean),
ob/ob mice (ob/ob), or ob/ob mice
treated with adiponectin (ob/ob + Ad)
for 2 weeks were subjected to a glu-
cose-tolerance test (a) and insulin-
tolerance test (b). The ratios of liver-
to-body weight (c), hepatic TG
contents (d), and serum ALT levels (e)
were determined at necropsy. Hepat-
ic mRNA expression of TNF-α (f) was
analyzed as in Figure 5. The results
were from five to seven mice per
group. *P < 0.05, **P < 0.01 for
adiponectin-treated ob/ob mice versus
untreated ob/ob mice.
Table 1
Effects of adiponectin on body weight gains, food intake, and plasma concen-
trations of glucose, insulin, TG, and FFA in ob/ob mice
Group
Parameters Lean ob/ob ob/ob + Ad
TG (mg/ml) 91.3 ± 15.2 227.2 ± 38.7 152.0 ± 23.1A
FFA (mM) 0.82 ± 0.07 1.61 ± 0.20 1.18 ± 0.08A
Glucose (mg/dl) 147.8 ± 9.2 200.9 ± 16.4 186.1 ± 12.7
Insulin (ng/ml) 0.31 ± 0.04 16.2 ± 0.7 16.4 ± 0.5
Daily food intake (g) 2.85 ± 0.26 8.40 ± 0.71 8.94 ± 0.56
Daily body weight gain (g) 0.114 ± 0.035 0.289 ± 0.036 0.274 ± 0.057
AP < 0.05 adiponectin-treated ob/ob mice versus untreated ob/ob mice.
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vation of the protein kinase A (PKA) pathway (50).
PKA activation can dramatically decrease adiponectin
expression in vivo as well as in vitro (51, 52).
Our results demonstrated that the protective role of
adiponectin against liver injury is partly due to its antag-
onistic effect against TNF-α. Administration of adi-
ponectin suppressed TNF-α expression in liver tissue
and also decreased circulating concentrations of TNF-α
(Figure 5). This finding is consistent with a recent report,
which demonstrated that TNF-α production was
markedly increased in adiponectin knockout mice (19).
An in vitro study also indicated that treatment with
adiponectin significantly inhibited LPS-induced TNF-α
production in cultured macrophages (24).
In addition to suppressing TNF-α production,
adiponectin may directly antagonize the damage-caus-
ing effects of TNF-α within the liver tissue. Indeed,
adiponectin and TNF-α elicit many opposing effects.
TNF-α is a causative factor of insulin resistance, where-
as adiponectin increases insulin sensitivity (53).
Adiponectin has antiatherogenic activity (54, 55),
whereas TNF-α contributes to the onset of atheroscle-
rosis (56). The direct antagonism between these two
hormones has been demonstrated recently in muscle
cells, where each impedes the other’s action in the reg-
ulation of glucose and lipid metabolism (19). In hepat-
ic tissue TNF-α has been found to decrease insulin sen-
sitivity and to enhance gluconeogenesis, whereas
adiponectin has completely opposite functions (22).
Thus, our findings further reinforce the concept that
these two structurally similar hormones have opposite
physiological effects and also suggest that increasing
the ratio of plasma adiponectin/TNF-α will be useful
for the treatment of alcoholic hepatitis.
It is important to note that the marked depletion of
hepatic fat accumulation by adiponectin cannot be
explained solely by its antagonistic effects against 
TNF-α. Growing evidence suggests that adiponectin
can regulate hepatocyte metabolism. Treatment of pri-
mary rat hepatocytes with adiponectin in vitro dra-
matically increased the sensitivity of insulin to inhibit
gluconeogenesis (23). Infusion of adiponectin into
mice suppressed the expression of hepatic mRNAs cor-
responding to the gluconeogenic enzymes phospho-
enolpyruvate carboxykinase and glucose-6-phos-
phatase (57). In the present study, we have demon-
strated that administration of adiponectin can regulate
hepatic fatty acid metabolism in vivo. Adiponectin
infusion attenuated the activities of two rate-limiting
enzymes involved in fatty acid synthesis, including FAS
and ACC (Figure 7). Notably, hepatic mRNA abun-
dance of FAS was suppressed following adiponectin
treatment, whereas the expression of ACC was not
affected. This result suggests that adiponectin sup-
presses these two hepatic enzymes via different path-
ways. The suppression of FAS is due to its decreased
gene expression, whereas inactivation of ACC activity
perhaps is caused by a posttranscriptional mechanism.
Indeed, a more recent study has shown that full-length
adiponectin can activate 5′-AMP–activated kinase in rat
hepatocytes, which in turn will phosphorylate ACC and
attenuate the activity of this enzyme (58).
A truncated COOH-terminal globular-region frag-
ment of adiponectin has been shown to increase fatty
acid β oxidation in muscle (21). In the present study,
we showed that full-length adiponectin generated
from mammalian cells could increase hepatic fatty
acid oxidation in vivo, which is partly caused by acti-
vation of CPT I, a rate-limiting enzyme involved in
this metabolic pathway (Figure 6). The mechanism
underlying adiponectin-mediated elevation of CPT I
activity is currently unclear. Hepatic expression of
this enzyme was not altered following adiponectin
treatment (data not shown). It is possible that
adiponectin-mediated inactivation of ACC in the
liver cells (Figure 7) will lead to a decrease in the con-
centration of its product malonyl-CoA (a potent
inhibitor of CPT I) and will thus induce fatty acid
oxidation in this tissue (59).
Figure 9
Relationship between plasma levels of adiponectin and ALT in 90
morbidly obese Chinese individuals (45 male and 45 female). 
r, Spearman correlation.
Figure 10
Schematic representation of the potential mechanisms that underlie
the hepatoprotective actions of adiponectin.
In addition to suppressing lipogenesis and activat-
ing fatty acid oxidation, other metabolic effects of
adiponectin might also contribute to its lipid-deplet-
ing effects. For instance, adiponectin can enhance the
clearance of circulating lipids by triggering its muscu-
lar combustion (21), which in turn will decrease the
source of fatty acid influx into the liver. It can also
downregulate the hepatic expression of CD36 (Figure
7), a protein responsible for transportation of fatty
acids into tissues. These results collectively demon-
strate that adiponectin abrogates alcohol-induced
fatty liver by regulating multiple, coordinated, meta-
bolic pathways (Figure 10).
The protective role of adiponectin against fatty liver
diseases was confirmed in a nonalcoholic obese
mouse model with insulin resistance and dyslipi-
demia (Figure 8). Although the primary etiology in
the ob/ob mouse is due to the deficiency of another
fat-derived hormone, leptin, adiponectin replacement
therapy can partly compensate for leptin for alleviat-
ing hepatomegaly and steatosis and for reducing
serum ALT levels. In addition, our results showed that
infusion of adiponectin increased insulin sensitivity
and alleviated hyperlipidemia in this model. This
result is consistent with a recent transgenic study that
demonstrated amelioration of insulin resistance and
dyslipidemia after crossing ob/ob mice with globular
domain adiponectin transgenic mice (44).
Fatty liver disease is a common finding in patients
and various animal models with obesity, insulin resist-
ance, diabetes, and dyslipidemia (60). Liver test abnor-
malities are found in up to 70% of diabetic patients,
the majority attributable to fatty liver. Liver biopsies
show steatosis in over 75% of morbidly obese subjects
(61). In fact, hepatic steatosis has been proposed as an
important feature of the insulin-resistance syndrome
or syndrome X. A cross-sectional study of 551 severely
obese individuals found that the risk of hepatic steato-
sis increased exponentially with each addition of the
four components (type 2 diabetes, hyperlipidemia, vis-
ceral obesity, and hypertension) of the insulin-resist-
ance syndromes (62). Notably, it has been reported
that metformin, an oral antidiabetic drug that reduces
hyperinsulinemia and improves hepatic insulin resist-
ance, is effective in alleviating fatty liver diseases in
patients and animal models (40, 63). The strong asso-
ciation between insulin resistance and fatty liver 
disease is further confirmed by our finding that
adiponectin, which has insulin-sensitizing and glu-
cose-lowering activities, can potently ameliorate hepat-
ic steatosis. The fact that the plasma levels of
adiponectin inversely correlate with that of ALT in
morbidly obese subjects (Figure 9) suggests that
hypoadiponectinemia is at least partly responsible for
hepatic steatosis and liver injury in this population.
This clinical finding is consistent with a recent study,
which demonstrated that adiponectin deficiency is
closely correlated with hepatic lipid accumulation in
patients with insulin resistance (64).
In summary, our present study demonstrated, we
believe for the first time, that the fat-derived hormone
adiponectin is effective in alleviating alcohol- and obe-
sity-induced hepatomegaly, steatosis, and serum ALT
abnormality in mice. Notably, in CCl4–treated mouse
liver, a large amount of adiponectin was found to accu-
mulate and bind at the extracellular matrix of hepato-
cytes (65), suggesting that it may also act as an anti-
inflammatory hormone that participates in the repair
process of CCl4-induced liver injury. Therefore, in addi-
tion to its antidiabetic and antiatherogenic potentials,
adiponectin or its agonists may represent a novel agent
for the treatment of liver diseases.
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